Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-1 beta-specific partial agonists defined by site-directed mutagenesis studies

F Guinet1, J D Guitton, N Gault

  • 1Department of Biotechnology, Rhône-Poulenc Rorer, Vitry-sur-Seine, France.

European Journal of Biochemistry
|February 1, 1993
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial colonisation rewires the composition and content of poplar root exudates, root and shoot metabolomes.

Microbiome·2024
Same author

Confocal Laser Scanning Microscopy Approach to Investigate Plant-Fungal Interactions.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Lipoteichoic acid depletion in <i>Lactobacillus</i> impacts cell morphology and stress response but does not abolish mercury surface binding.

Beneficial microbes·2020
Same author

Cardiac troponin I as an early prognosis biomarker after trauma: a retrospective cohort study.

British journal of anaesthesia·2018
Same author

Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
Same author

Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2017

Researchers identified key residues in interleukin-1 beta (IL-1β) that reduce cartilage matrix destruction in arthritis. Mutants showed reduced activity in cartilage assays, offering potential therapeutic targets for inflammatory joint diseases.

Area of Science:

  • Biochemistry
  • Immunology
  • Structural Biology

Background:

  • Monocyte-derived interleukin-1 (IL-1) plays a critical role in cartilage matrix destruction in articular diseases like rheumatoid arthritis and osteoarthritis.
  • Understanding the structure-activity relationships of IL-1 is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify topologically conserved residues in IL-1 polypeptides.
  • To investigate the biological activities of IL-1 beta mutants with altered structures.
  • To explore potential therapeutic strategies for reducing cartilage degradation.

Main Methods:

  • Sequence analysis using Parker's algorithm and hydrophobic cluster analysis.
  • Site-directed mutagenesis of conserved and loop residues in human IL-1 beta.

Related Experiment Videos

  • Expression and purification of mutant polypeptides in Escherichia coli.
  • Assessment of biological activities including cell binding, lymphocyte activation, and cartilage matrix assays.

    • Main Results:

    • Twenty human IL-1 beta mutant polypeptides were generated and characterized.
    • Four mutants exhibited significantly reduced activity in cartilage matrix degradation assays.
    • These mutants maintained binding affinity to chondrocytes but showed reduced effects on cartilage matrix.
    • Some mutants acted as partial agonists, with low affinity for thymocytes.

    Conclusions:

    • Specific residues in IL-1 beta are critical for its cartilage-degrading activity.
    • Mutants with reduced cartilage matrix degradation show potential as therapeutic agents for osteoarthritis and rheumatoid arthritis.
    • Targeting these specific IL-1 beta residues could lead to novel treatments for inflammatory joint diseases.